Supplementary Table 4. Effect of ticagrelor-aspirin compared with clopidogrel-aspirin on efficacy outcomes within 1 year stratified by previous antiplatelet therapy among patients with or without ICAS

Outcomes	CA	TA	Crude HR (95% CI)	Adjusted HR (95% CI)*	Adjusted *P* for interaction*
Stroke					
ICAS					0.091
Without Pap	132 (12.9)	121 (11.8)	0.90 (0.71–1.15)	0.88 (0.69–1.13)	
With Pap	23 (14.8)	19 (10.5)	0.69 (0.37–1.26)	0.67 (0.36–1.24)	
Non-ICAS					0.002
Without Pap	123 (7.8)	67 (4.2)	0.52 (0.39–0.69)	0.52 (0.39–0.69)	
With Pap	12 (6.5)	17 (9.4)	1.48 (0.71–3.10)	1.84 (0.85–3.98)	
Composite vascular events†					
ICAS					0.479
Without Pap	166 (16.2)	137 (13.4)	0.81 (0.64–1.01)	0.78 (0.62–0.98)	
With Pap	25 (16.1)	25 (13.8)	0.84 (0.48–1.46)	0.79 (0.45–1.39)	
Non-ICAS					0.013
Without Pap	153 (9.6)	92 (5.8)	0.59 (0.46–0.77)	0.59 (0.46–0.77)	
With Pap	18 (9.7)	20 (11.1)	1.16 (0.61–2.19)	1.44 (0.74–2.81)	
Ischemic stroke					
ICAS					0.093
Without Pap	130 (12.7)	118 (11.5)	0.89 (0.70–1.15)	0.87 (0.68–1.12)	
With Pap	23 (14.8)	9 (10.5)	0.69 (0.37–1.26)	0.67 (0.36–1.24)	
Non-ICAS					0.003
Without Pap	123 (7.8)	67 (4.2)	0.54 (0.40–0.72)	0.54 (0.40–0.72)	
With Pap	12 (6.5)	17 (9.4)	1.48 (0.71–3.10)	1.84 (0.85–3.98)	
Disabling stroke‡					
ICAS					0.110
Without Pap	48 (4.7)	59 (5.8)	1.21 (0.82–1.77)	1.16 (0.79–1.70)	
With Pap	9 (5.8)	9 (5.0)	0.83 (0.33–2.10)	0.80 (0.32–2.03)	
Non-ICAS					0.031
Without Pap	34 (2.1)	16 (1.0)	0.46 (0.26–0.84)	0.47 (0.26–0.86)	
With Pap	4 (2.2)	7 (3.9)	1.83 (0.54–6.26)	2.06 (0.59–7.18)	

Values are presented as n (%) unless otherwise indicated.
CA, clopidogrel-aspirin; TA, ticagrelor-aspirin; HR, hazard ratio; CI, confidence interval; ICAS, intracranial arterial stenosis; Pap, previous antiplatelet therapy; TIA, transient ischemic attack; mRS, modified Rankin Scale.
*Adjusted for age, Han ethnic, sex, body mass index, current smoking status, medical history of hypertension, diabetes, dyslipidemia, myocardial infarction, ischemic stroke, TIA, type of *CYP2C19* loss-of-function allele carrier, and previous lipid-lowering therapy; †Composite vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction, and vascular death; ‡A stroke was defined as disabling if the patient had an mRS score of greater than 1 (indicating death or any degree of disability).